...
search icon
  • Apple, Inc AAPL
  • S&P 500 ETF Trust SPDR SPY
  • Alphabet Inc. - Class A Shares GOOGL
  • Microsoft Corporation MSFT
  • Meta Platforms Inc META
  • Netflix, Inc. NFLX
  • Amazon.com Inc. AMZN
  • Spotify Technology SA SPOT
    bbot-img

    BridgeBio Oncology Therapeutics, Inc., Common Stock

    BBOT

    NMQ

    $10.95

    -$0.3

    (-2.67%)

    1D

    Analyst Forecast

    Overview Returns Financials Ratios News FAQs

    Price Chart

    Key Metrics

    Market Cap info-icon
    This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
     $890.96M
    P/E Ratio info-icon
    This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
     0
    Volume info-icon
    This is the total number of shares traded during the most recent trading day.
     57.62K
    Avg Volume info-icon
    This is the average number of shares traded during the most recent 30 days.
     0
    Dividend Yield info-icon
    This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
     0.00%
    Beta info-icon
    This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
     0
    52-week Range info-icon
    This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
    $8.7 L
    $13.18 H
    $10.95

    About BridgeBio Oncology Therapeutics, Inc., Common Stock

    BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I clinical trial for treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS pancreatic ductal adenocarcinoma (PDAC), KRAS mutant colorectal cancer (CRC), and KRAS mutant NSCLC. It is also developing BBO-11818, an orally bioavailable pan KRAS on/off inhibitor that is in Phase I clinical trial to treat patients with KRASG12D and KRASG12V mutant NSCLC, PDAC, and CRC. The company was founded in 2016 is headquartered in South San Francisco, California. more

    Returns

    Data is not properly formatted.

    Financials

    Dec '21Dec '22Dec '23Dec '24
    Total Revenue----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
    Cost of Revenue----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
    Gross Profit----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
    Gross Margin----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
    Operating Expenses43.36K3.52K41.69K584.39K[{"date":"2021-12-31","value":7.42,"profit":true},{"date":"2022-12-31","value":0.6,"profit":true},{"date":"2023-12-31","value":7.13,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Operating Income(43.36K)-(41.69K)(584.00K)[{"date":"2021-12-31","value":-4335700,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-4169200,"profit":false},{"date":"2024-12-31","value":-58400000,"profit":false}]
    Total Non-Operating Income/Expense---14.56M[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
    Pre-Tax Income(43.36K)(3.52K)(41.69K)7.60M[{"date":"2021-12-31","value":-0.57,"profit":false},{"date":"2022-12-31","value":-0.05,"profit":false},{"date":"2023-12-31","value":-0.55,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
    Income Taxes----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
    Income After Taxes----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
    Income From Continuous Operations--(64.70M)(74.28M)[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-6469900000,"profit":false},{"date":"2024-12-31","value":-7427500000,"profit":false}]
    Income From Discontinued Operations----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
    Net Income(43.36K)(3.52K)(41.69K)7.60M[{"date":"2021-12-31","value":-0.57,"profit":false},{"date":"2022-12-31","value":-0.05,"profit":false},{"date":"2023-12-31","value":-0.55,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
    EPS (Diluted)---0.32[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]

    Ratios

    Liquidity

    These ratios help you determine the liquidity of the company. Higher is better.

    BBOT
    Cash Ratio 0.25
    Current Ratio 0.33

    Asset Efficiency

    These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

    BBOT
    ROA (LTM) 0.00%
    ROE (LTM) 0.00%

    Liabilities

    These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

    BBOT
    Debt Ratio Lower is generally better. Negative is bad. 0.04
    Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.04

    Valuation

    These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

    BBOT
    Trailing PE NM
    Forward PE NM
    P/S (TTM) 0.00
    P/B 0.00
    EV/R 0.00
    EV/Ebitda NM

    Discover more

    Tsla

    Tesla, Inc.
    aaple

    Apple, Inc.
    GOOGL

    Alphabet Inc. - Class A Shares
    META

    Meta Platforms Inc
    AMZN

    Amazon.com Inc.
    Microsoft

    Microsoft Corporation
    NVDA

    NVIDIA Corporation
    BRK

    Berkshire Hathaway Inc. Hld B
    LLY

    Eli Lilly and Company

    FAQs

    What is BridgeBio Oncology Therapeutics, Inc. share price today?

    BridgeBio Oncology Therapeutics, Inc. (BBOT) share price today is $10.95

    Can Indians buy BridgeBio Oncology Therapeutics, Inc. shares?

    Yes, Indians can buy shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) on Vested. To buy BridgeBio Oncology Therapeutics, Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BBOT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

    Can Fractional shares of BridgeBio Oncology Therapeutics, Inc. be purchased?

    Yes, you can purchase fractional shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) via the Vested app. You can start investing in BridgeBio Oncology Therapeutics, Inc. (BBOT) with a minimum investment of $1.

    How to invest in BridgeBio Oncology Therapeutics, Inc. shares from India?

    You can invest in shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) via Vested in three simple steps:

    • Click on Sign Up or Invest in BBOT stock at the top of this page
    • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
    • Transfer USD funds to your US Brokerage account and start investing in BridgeBio Oncology Therapeutics, Inc. shares
    What is BridgeBio Oncology Therapeutics, Inc. 52-week high and low stock price?

    The 52-week high price of BridgeBio Oncology Therapeutics, Inc. (BBOT) is $13.18. The 52-week low price of BridgeBio Oncology Therapeutics, Inc. (BBOT) is $8.7.

    What is BridgeBio Oncology Therapeutics, Inc. price-to-book (P/B) ratio?

    The price-to-book (P/B) ratio of BridgeBio Oncology Therapeutics, Inc. (BBOT) is 0.00

    What is the Market Cap of BridgeBio Oncology Therapeutics, Inc.?

    The market capitalization of BridgeBio Oncology Therapeutics, Inc. (BBOT) is $890.96M

    What is BridgeBio Oncology Therapeutics, Inc.’s stock symbol?

    The stock symbol (or ticker) of BridgeBio Oncology Therapeutics, Inc. is BBOT

    Feedback

    Signup to access all features and start your US investing journey!

    • Open your account in minutes
    • Take your portfolio global, starting at just $1
    Get started

    Add ticker to compare

    Scroll to Top